RxDoctor Payments Data

Krista Bolton, NP

Family Medicine · la Follette, TNNPI 1639647464

Payments from drug & device makers

$2,434in general payments, 2019–2025

Across 121 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$391
  • Novo Nordisk$382
  • AstraZeneca$244
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$221
  • Amgen$172
  • Pfizer$137
  • plus $887 from 21 others

What the payments were for

  • Food & beverage$2,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,434 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$37,296
Medicare patients
77
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$60,092
OzempicSemaglutide29$40,380
EliquisApixaban27$31,604
JardianceEmpagliflozin23$24,816
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$18,697
RybelsusSemaglutide12$12,300
LinzessLinaclotide14$11,944
Emgality PenGalcanezumab-Gnlm12$7,932
Breo ElliptaFluticasone/Vilanterol16$7,874
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,429
XareltoRivaroxaban11$5,932
Spiriva RespimatTiotropium Bromide11$5,439
Levothyroxine Sodium289$2,351
Albuterol Sulfate HfaAlbuterol Sulfate82$2,066
Omeprazole137$1,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$62$60,09250 claims
Novo NordiskOzempic, Rybelsus$382$52,68041 claims
PfizerEliquis$137$31,60427 claims
Boehringer IngelheimJardiance, Spiriva Respimat$35$30,25534 claims
GSKTrelegy Ellipta, Breo Ellipta$74$26,57131 claims
AbbVieLinzess, Synthroid$391$13,00027 claims
Johnson & JohnsonXarelto$29$5,93211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in la Follette

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →